Scientists finally explain why a promising class of cancer drugs keeps failing in patients
BET inhibitors (drugs targeting BET bromodomain proteins) showed extraordinary promise in early cancer research — they could suppress the expression of potent oncogenes like MYC. But clinical trials have repeatedly disappointed, with patients not responding as expected. A new study may have found…
Scientists finally explain why a promising class of cancer drugs keeps failing in patients
BET inhibitors (drugs targeting BET bromodomain proteins) showed extraordinary promise in early cancer research — they could suppress the expression of potent oncogenes like MYC. But clinical trials have repeatedly disappointed, with patients not responding as expected. A new study may have found the key reason why.
Researchers discovered that two closely related proteins targeted by BET inhibitors — BRD2 and BRD4 — have fundamentally different functions. BRD2 acts like a 'stage manager,' helping prepare genes for activation, while BRD4 acts as the trigger that turns gene expression on. Current BET inhibitors block both simultaneously, which creates unpredictable and counterproductive effects on gene regulation — disrupting the preparation step (BRD2) while also trying to suppress the activation step (BRD4).
This mechanistic insight suggests that more selective inhibitors targeting only BRD4 (or using BRD2 as an activator rather than inhibiting it) could be more effective cancer drugs — and explains the clinical failures of broad BET inhibitors.
Key Findings
- BRD2 and BRD4 have distinct, non-redundant functions in gene regulation
- BRD2 acts as a gene 'stage manager' (preparing activation) while BRD4 triggers actual transcription
- Current BET inhibitors block both BRD2 and BRD4, creating unpredictable effects
- Differential BRD2/BRD4 roles explain clinical underperformance of pan-BET inhibitors
- More selective BRD4-specific inhibitors may be more effective cancer drugs
Implications
This mechanistic insight could revive the BET inhibitor drug class. Selective BRD4 inhibitors — or strategies that preserve BRD2 activity while targeting BRD4 — should be tested in cancers where BET inhibitors previously showed preclinical promise. This is relevant for MYC-driven cancers including many leukemias, lymphomas, and solid tumors.
Caveats
Brief news summary; details of the research models and specific cancers studied not available. Mechanistic finding needs validation in clinical settings. Development of truly selective BRD4 vs BRD2 inhibitors is technically challenging. Summary based on abstract only.
Source: ScienceDaily Cancer — 2026-04-10
